tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature

• Published in: Biomedicines Vol. 9; no. 12; p. 1811
• Main Authors: Karousi, Paraskevi, Papanota, Aristea-Maria, Artemaki, Pinelopi I, Liacos, Christine-Ivy, Patseas, Dimitrios, Mavrianou-Koutsoukou, Nefeli, Liosi, Aikaterini-Anna, Kalioraki, Maria-Anna, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Kastritis, Efstathios, Dimopoulos, Meletios-Athanasios, Scorilas, Andreas, Terpos, Evangelos, Kontos, Christos K
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.12.2021; MDPI
• Subjects: Biomarkers; bone disease; Bone diseases; Bone marrow; Cell proliferation; Cytokines; hematologic malignancy; Heparan sulfate; Malignancy; Multiple myeloma; Plasma; plasma cell dyscrasia; Plasma cells; Polyadenylation; Prognosis; small non-coding RNAs (sncRNAs); Transfer RNA; Transplants & implants; tRNA; tRNA derivative (tDR); tRNA-derived RNA fragment (tRF); United States > US; gene ontology (GO); small non-coding RNAs (sncRNAs); molecular biomarker; plasma cell dyscrasia; post-transcriptional regulator; hematologic malignancy; prognosis; bone disease; tRNA derivative (tDR); tRNA-derived RNA fragment (tRF)
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines9121811

Multiple myeloma (MM) is a hematologic malignancy arising from the clonal proliferation of malignant plasma cells. tRNA-derived RNA fragments (tRFs) constitute a class of small non-coding RNAs, deriving from specific enzymatic cleavage of tRNAs. To the best of our knowledge, this is one of few studies to uncover the potential clinical significance of tRFs in MM. Total RNA was extracted from CD138+ plasma cells of MM and smoldering MM patients, and in vitro polyadenylated. First-strand cDNA synthesis was performed, priming from an oligo-dT-adaptor sequence. Next, real-time quantitative PCR (qPCR) assays were developed for the quantification of six tRFs. Biostatistical analysis was performed to assess the results and in silico analysis was conducted to predict the function of one of the tRFs. Our results showed that elevated levels of five out of six tRFs are indicators of favorable prognosis in MM, predicting prolonged overall survival (OS), while two of them constitute potential molecular biomarkers of favorable prognosis in terms of disease progression. Moreover, three tRFs could be used as surrogate prognostic biomarkers along with the R-ISS staging system to predict OS. In conclusion, tRFs show molecular biomarker utility in MM, while their mechanisms of function merit further investigation.